
Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated March 28, 2024, titled "Caplin Steriles Limited, our Subsidiary, gets USFDA approval for Ketorolac tromethamine Ophthalmic Solution 0.5%".
Filed with NSE ·

Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated March 28, 2024, titled "Caplin Steriles Limited, our Subsidiary, gets USFDA approval for Ketorolac tromethamine Ophthalmic Solution 0.5%".
6ix hasn’t read this filing yet.
Caplin Point Laboratories Limited on 6ix
Follow Caplin Point Laboratories into a list and get an email when it puts out news.
Follow Caplin Point Laboratories